SJ-600 Series (with SillaJen)
Oncology
Pre-clinicalActive
Key Facts
About ReiThera
ReiThera is a dual-focus Italian biotech, functioning both as a specialized CDMO for viral vectors and as a developer of its own therapeutic candidates. Its core expertise lies in viral vector engineering and scalable GMP manufacturing for adenoviruses, AAV, Lentivirus, MVA, and Herpes Simplex vectors. The company is advancing a clinical-stage HIV vaccine candidate in partnership with major research institutes and is actively involved in outbreak response efforts, such as for Marburg virus, while serving a global client base from its state-of-the-art facility in Rome.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |
| Personalized Medicine Assays (Patient-Derived Explants) | Aurita Bioscience | Research-Use Only |
| CDK2-CyclinE1 & CDK2-CyclinA2 Assay | Aurora Biolabs | Commercial |
| POLQ & eIF4E Assay | Aurora Biolabs | Commercial |
| PKMYT1 & WEE1 Assay | Aurora Biolabs | Commercial |
| NTP42 | ATXA Therapeutics | Preclinical |
| Athebody® DARPins for pHLA-binding T-Cell Engagers | Athebio | Pre-clinical |
| Dual-Targeting CAR-T Programs | Factor Bioscience | Pre-clinical |